Sanjay Popat
@drsanjaypopat.bsky.social
Thoracic Oncologist, Royal Marsden Hospital | Professor, Institute of Cancer Research | Past chair, British Thoracic Oncology Group | Views are my own
Reposted by Sanjay Popat
www.sciencedirect.com/science/arti... Now in press in Journal of Thoracic Oncology - a hypothesis I’ve presented at meetings for a couple of years but never put in writing before.
Hiding in Plain Sight: The Neuro-Protective Benefit of Tyrosine Kinase Inhibition in Non–Neurotrophic Receptor Tyrosine Kinase-Driven Lung Cancers
www.sciencedirect.com
January 21, 2026 at 1:14 AM
www.sciencedirect.com/science/arti... Now in press in Journal of Thoracic Oncology - a hypothesis I’ve presented at meetings for a couple of years but never put in writing before.
Reposted by Sanjay Popat
Pleased to publish a case report exploring a number of interesting elements of ERBB2 (HER2) mutated NSCLC on @jtoonline.bsky.social with @drsanjaypopat.bsky.social and @dralexiusjohn.bsky.social
www.jtocrr.org/article/S266...
www.jtocrr.org/article/S266...
Acquired ERBB2 amplification and overexpression as on-target resistance mechanisms to zongertinib with subsequent response to trastuzumab deruxtecan; a case report
A number of drugs are in development for the treatment of ERBB2(HER2)-mutated Non-Small
Cell Lung Cancer (NSCLC) including antibody-drug conjugates (ADCs) such as trastuzumab
deruxtecan (T-DXd) and ty...
www.jtocrr.org
January 24, 2026 at 12:31 PM
Pleased to publish a case report exploring a number of interesting elements of ERBB2 (HER2) mutated NSCLC on @jtoonline.bsky.social with @drsanjaypopat.bsky.social and @dralexiusjohn.bsky.social
www.jtocrr.org/article/S266...
www.jtocrr.org/article/S266...
Reposted by Sanjay Popat
pubmed.ncbi.nlm.nih.gov/41609978/
Delighted to explore the complex landscape of EGFRm NSCLC in 2026 with @drsanjaypopat.bsky.social and @dralexiusjohn.bsky.social
Mechanisms of resistance
FLAURA vs MARIPOSA vs FLAURA 2
Decision making after these regimens
Genomic informed and agnostic approaches
Delighted to explore the complex landscape of EGFRm NSCLC in 2026 with @drsanjaypopat.bsky.social and @dralexiusjohn.bsky.social
Mechanisms of resistance
FLAURA vs MARIPOSA vs FLAURA 2
Decision making after these regimens
Genomic informed and agnostic approaches
Current and Emerging Treatment Landscape of Common EGFR-Mutated Advanced Non-small Cell Lung Cancer - PubMed
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has been standard of care as monotherapy for EGFR-mutated advanced non-small cell lung cancer since reporting of the FLAURA phase III clinical trial, which demonstrated superiority over first-generatio …
pubmed.ncbi.nlm.nih.gov
January 30, 2026 at 7:26 PM
pubmed.ncbi.nlm.nih.gov/41609978/
Delighted to explore the complex landscape of EGFRm NSCLC in 2026 with @drsanjaypopat.bsky.social and @dralexiusjohn.bsky.social
Mechanisms of resistance
FLAURA vs MARIPOSA vs FLAURA 2
Decision making after these regimens
Genomic informed and agnostic approaches
Delighted to explore the complex landscape of EGFRm NSCLC in 2026 with @drsanjaypopat.bsky.social and @dralexiusjohn.bsky.social
Mechanisms of resistance
FLAURA vs MARIPOSA vs FLAURA 2
Decision making after these regimens
Genomic informed and agnostic approaches
There’s a lot going on and new in #lungcancer. Be there to understand the latest developments!
📣 Registration for #ELCC26 is open! Join us in Copenhagen, 25–28 March, for cutting-edge science and global networking.
⏰ Early rates until 21 Jan.
🔗 https://ow.ly/mAHv50XBJQL
Don’t miss your chance to shape the future of #LungCancer care!
⏰ Early rates until 21 Jan.
🔗 https://ow.ly/mAHv50XBJQL
Don’t miss your chance to shape the future of #LungCancer care!
December 16, 2025 at 1:56 PM
There’s a lot going on and new in #lungcancer. Be there to understand the latest developments!
Fellows, writing a manuscript with me? The 10 golden rules never grow old
October 28, 2025 at 7:06 AM
Fellows, writing a manuscript with me? The 10 golden rules never grow old
For those of you wondering why newer antibodies are now called -tugs -barts -migs and -ments not -mabs, this is the official @who.int INN explainer
tinyurl.com/49bxfn4t
tinyurl.com/49bxfn4t
September 5, 2025 at 3:52 AM
For those of you wondering why newer antibodies are now called -tugs -barts -migs and -ments not -mabs, this is the official @who.int INN explainer
tinyurl.com/49bxfn4t
tinyurl.com/49bxfn4t
Reposted by Sanjay Popat
🌍 Why do people who’ve never smoked get lung cancer?
Our first session dives into epidemiology, environmental aetiology, and early detection.
With @ruthstraussfdn.bsky.social
🧠 #BTOG2025 | 📍 London | 📅 13 Nov
🔗 www.btog.org/non-smo...
#LungCancer #LCSM #NonSmokingLungCancer
Our first session dives into epidemiology, environmental aetiology, and early detection.
With @ruthstraussfdn.bsky.social
🧠 #BTOG2025 | 📍 London | 📅 13 Nov
🔗 www.btog.org/non-smo...
#LungCancer #LCSM #NonSmokingLungCancer
July 31, 2025 at 1:34 PM
🌍 Why do people who’ve never smoked get lung cancer?
Our first session dives into epidemiology, environmental aetiology, and early detection.
With @ruthstraussfdn.bsky.social
🧠 #BTOG2025 | 📍 London | 📅 13 Nov
🔗 www.btog.org/non-smo...
#LungCancer #LCSM #NonSmokingLungCancer
Our first session dives into epidemiology, environmental aetiology, and early detection.
With @ruthstraussfdn.bsky.social
🧠 #BTOG2025 | 📍 London | 📅 13 Nov
🔗 www.btog.org/non-smo...
#LungCancer #LCSM #NonSmokingLungCancer
Reposted by Sanjay Popat
The #ASCO25 #OncoAlertTOP10 Abstracts in #LungCancer 🫁 These are some of our picks of TOP abstracts we look forward to be presented at the upcoming ASCO Meeting in Chicago 🇺🇸
@biagioricciutimd.bsky.social
@stephenvliu.bsky.social
@drsanjaypopat.bsky.social
Ping
@drjnaidoo.bsky.social
@biagioricciutimd.bsky.social
@stephenvliu.bsky.social
@drsanjaypopat.bsky.social
Ping
@drjnaidoo.bsky.social
May 26, 2025 at 10:00 AM
The #ASCO25 #OncoAlertTOP10 Abstracts in #LungCancer 🫁 These are some of our picks of TOP abstracts we look forward to be presented at the upcoming ASCO Meeting in Chicago 🇺🇸
@biagioricciutimd.bsky.social
@stephenvliu.bsky.social
@drsanjaypopat.bsky.social
Ping
@drjnaidoo.bsky.social
@biagioricciutimd.bsky.social
@stephenvliu.bsky.social
@drsanjaypopat.bsky.social
Ping
@drjnaidoo.bsky.social
Reposted by Sanjay Popat
Thank you #LCS2025 in #KualaLumpur 🇲🇾 for hosting an informative & interactive lung cancer meeting! Always pleasure to meet colleagues who are keen to move our 🫁 field forward. #LCSM @apoddc @APCLC_2023
@stephanieplsaw @drdaviddwlee #BeungChulAhn #PJVoon #JenniferLeong @drsanjaypopat.bsky.social
@stephanieplsaw @drdaviddwlee #BeungChulAhn #PJVoon #JenniferLeong @drsanjaypopat.bsky.social
April 26, 2025 at 4:27 PM
Thank you #LCS2025 in #KualaLumpur 🇲🇾 for hosting an informative & interactive lung cancer meeting! Always pleasure to meet colleagues who are keen to move our 🫁 field forward. #LCSM @apoddc @APCLC_2023
@stephanieplsaw @drdaviddwlee #BeungChulAhn #PJVoon #JenniferLeong @drsanjaypopat.bsky.social
@stephanieplsaw @drdaviddwlee #BeungChulAhn #PJVoon #JenniferLeong @drsanjaypopat.bsky.social
Reposted by Sanjay Popat
❗️FLAURA2 approved by NICE❗️
Already on BlueTeq!
Now an option for 1L EGFR+ pts
Worth familiarising yourself with the higher risk subgroups that seemed to better with this regimen
Already on BlueTeq!
Now an option for 1L EGFR+ pts
Worth familiarising yourself with the higher risk subgroups that seemed to better with this regimen
NICE has recommended Osimertinib with pemetrexed and platinum-based chemotherapy (based on the FLAURA2 trial) as an option for untreated advanced NSCLC in adults whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.
April 10, 2025 at 10:34 AM
❗️FLAURA2 approved by NICE❗️
Already on BlueTeq!
Now an option for 1L EGFR+ pts
Worth familiarising yourself with the higher risk subgroups that seemed to better with this regimen
Already on BlueTeq!
Now an option for 1L EGFR+ pts
Worth familiarising yourself with the higher risk subgroups that seemed to better with this regimen
Great to see this important step for our EGFR mutant patients: FLAURA-2 approval by NICE. Interesting to note that the reimbursement (Blueteq form) allows a single cycle of chemo if clinically urgently indicated, but no access if PD on adjuvant osi. @btog.bsky.social @egfrpositiveuk.bsky.social
BTOG wishes to inform members of a new NICE release that has been published today.
Full details www.nice.org.uk/guidance/ind...
Full details www.nice.org.uk/guidance/ind...
Project documents | Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6328] | Guidance | NICE
www.nice.org.uk
April 10, 2025 at 10:19 AM
Great to see this important step for our EGFR mutant patients: FLAURA-2 approval by NICE. Interesting to note that the reimbursement (Blueteq form) allows a single cycle of chemo if clinically urgently indicated, but no access if PD on adjuvant osi. @btog.bsky.social @egfrpositiveuk.bsky.social
Very important dataset and a set forward to potential ambulatory delivery in the future.
Happy to share our recent #ESMOOpen paper on the #safety and #feasibility of #outpatient administration of #tarlatamab as part of the #DeLLphi300 study providing evidence that support less intensive monitoring at initiation of therapy. #LCSM 🫁 #SCLC 😀
doi.org/10.1016/j.es...
doi.org/10.1016/j.es...
April 5, 2025 at 11:06 AM
Very important dataset and a set forward to potential ambulatory delivery in the future.
Reposted by Sanjay Popat
HER2 mutated NSCLC increasingly important as a rest of new TKI show promising effectiveness in early phase trials
Riyaz Shah and I discuss these, and other HER2 targeted treatments
Riyaz Shah and I discuss these, and other HER2 targeted treatments
New Podcast Alert! BTOG Does ... HER2.
Featuring @tnewsomdavis.bsky.social, Dr Emma O'Dowd and Dr Riyaz Shah, listen wherever you get your podcasts (search 'BTOG') or online www.btog.org/btog-podcasts/ .
Featuring @tnewsomdavis.bsky.social, Dr Emma O'Dowd and Dr Riyaz Shah, listen wherever you get your podcasts (search 'BTOG') or online www.btog.org/btog-podcasts/ .
March 13, 2025 at 2:47 PM
HER2 mutated NSCLC increasingly important as a rest of new TKI show promising effectiveness in early phase trials
Riyaz Shah and I discuss these, and other HER2 targeted treatments
Riyaz Shah and I discuss these, and other HER2 targeted treatments
Very nice perspective from Drs Tannock, De Vries & colleagues @pmresearch-uhn.bsky.social in @thelancetoncol.bsky.social on dose optimization for oncology drugs: an area that @nihr.bsky.social should be evaluating, IMHO @nhsengland.bsky.social @bopa.org.uk
shorturl.at/aszUO
shorturl.at/aszUO
Dose optimisation to improve access to effective cancer medicines
Access to many cancer medicines on WHO's Essential Medicines List (EML) is restricted
because of price, especially in low-income and middle-income countries (LMICs). Other
cancer medicines that have b...
shorturl.at
March 9, 2025 at 11:41 AM
Very nice perspective from Drs Tannock, De Vries & colleagues @pmresearch-uhn.bsky.social in @thelancetoncol.bsky.social on dose optimization for oncology drugs: an area that @nihr.bsky.social should be evaluating, IMHO @nhsengland.bsky.social @bopa.org.uk
shorturl.at/aszUO
shorturl.at/aszUO
Reposted by Sanjay Popat
Was really looking forward to this session and it didn't disappoint! Always find related questions the hardest to answer in clinic. Just a shame they had the graveyard slot!
@bopa.org.uk take note of the speakers, they would be great additions to annual conference agenda
#BTOG25
@bopa.org.uk take note of the speakers, they would be great additions to annual conference agenda
#BTOG25
March 5, 2025 at 5:41 PM
Was really looking forward to this session and it didn't disappoint! Always find related questions the hardest to answer in clinic. Just a shame they had the graveyard slot!
@bopa.org.uk take note of the speakers, they would be great additions to annual conference agenda
#BTOG25
@bopa.org.uk take note of the speakers, they would be great additions to annual conference agenda
#BTOG25
Reposted by Sanjay Popat
Well #BTOG25 that’s a wrap for 2025 from #Belfast
Thanks to @btog.bsky.social for 3 fantastic years in Belfast
It’s been an absolute pleasure to have the BTOG community over with us for the last 3 years 🙏
Here’s to next year in Edinburgh!
@drsanjaypopat.bsky.social
@tnewsomdavis.bsky.social
Thanks to @btog.bsky.social for 3 fantastic years in Belfast
It’s been an absolute pleasure to have the BTOG community over with us for the last 3 years 🙏
Here’s to next year in Edinburgh!
@drsanjaypopat.bsky.social
@tnewsomdavis.bsky.social
March 5, 2025 at 5:36 PM
Well #BTOG25 that’s a wrap for 2025 from #Belfast
Thanks to @btog.bsky.social for 3 fantastic years in Belfast
It’s been an absolute pleasure to have the BTOG community over with us for the last 3 years 🙏
Here’s to next year in Edinburgh!
@drsanjaypopat.bsky.social
@tnewsomdavis.bsky.social
Thanks to @btog.bsky.social for 3 fantastic years in Belfast
It’s been an absolute pleasure to have the BTOG community over with us for the last 3 years 🙏
Here’s to next year in Edinburgh!
@drsanjaypopat.bsky.social
@tnewsomdavis.bsky.social
Reposted by Sanjay Popat
With the successful role out of the TLHC programme, we now have a growing cohort of stage 1 SCLC patients. Hopefully this will become even more common, and work needed to understand optimal patient management @drjnaidoo.bsky.social #BTOG25
March 5, 2025 at 12:28 PM
With the successful role out of the TLHC programme, we now have a growing cohort of stage 1 SCLC patients. Hopefully this will become even more common, and work needed to understand optimal patient management @drjnaidoo.bsky.social #BTOG25
Agree. A packed room for SCLC on the last day of a conference? Unheard of previously! Obviously all attending to listen to @annaminchom.bsky.social , @drjnaidoo.bsky.social ,& @stephenvliu.bsky.social!
@btog.bsky.social #BTOG25
@btog.bsky.social #BTOG25
SCLC was indeed the star at #BTOG25. Looking forward to the benefit (and challenges) of novel therapeutic strategies.
Translational studies to aid patient selection will now be more needed than ever.
Translational studies to aid patient selection will now be more needed than ever.
March 5, 2025 at 1:49 PM
Agree. A packed room for SCLC on the last day of a conference? Unheard of previously! Obviously all attending to listen to @annaminchom.bsky.social , @drjnaidoo.bsky.social ,& @stephenvliu.bsky.social!
@btog.bsky.social #BTOG25
@btog.bsky.social #BTOG25
Reposted by Sanjay Popat
@annaminchom.bsky.social on newer small cell therapeutic strategies and management of CRS and ICANS as specific TRAEs With thought around timings of dose delivery and education of AOS teams and patients, safely deliverable within the NHS
#BTOG25
#BTOG25
March 5, 2025 at 12:56 PM
@annaminchom.bsky.social on newer small cell therapeutic strategies and management of CRS and ICANS as specific TRAEs With thought around timings of dose delivery and education of AOS teams and patients, safely deliverable within the NHS
#BTOG25
#BTOG25
Great job, team! @btog.bsky.social #BTOG25
Excellent conference at #BTOG25 My pleasure to present our data on SCLC, Mesothelioma and resectable NSCLC from The Royal Marsden
March 5, 2025 at 1:46 PM
Great job, team! @btog.bsky.social #BTOG25
Reposted by Sanjay Popat
Professor @drjnaidoo.bsky.social welcomed to the #BTOG25 stage as a Lung Cancer Legend & doesn’t disappoint. Lots of discussion on how we turn discussions on Small Cell Lung Cancer on its head. Lots of optimism in #SCLC coming from new standards & future treatments. #LCSM
March 5, 2025 at 1:00 PM
Professor @drjnaidoo.bsky.social welcomed to the #BTOG25 stage as a Lung Cancer Legend & doesn’t disappoint. Lots of discussion on how we turn discussions on Small Cell Lung Cancer on its head. Lots of optimism in #SCLC coming from new standards & future treatments. #LCSM
Reposted by Sanjay Popat
At #BTOG25 & I tringied by Matt’s comment on the fact that GP practices who request more chest X-rays have less stage III/IV #lungcaner disease? Read more here! www.respiratoryfutures.org.uk/features/dia...
Diagnosing Lung Cancer: X-rays & CT Scans | Respiratory Futures
Learn how chest x-rays and CT scans aid in diagnosing lung cancer and the role of primary care in early detection.
www.respiratoryfutures.org.uk
March 5, 2025 at 10:28 AM
At #BTOG25 & I tringied by Matt’s comment on the fact that GP practices who request more chest X-rays have less stage III/IV #lungcaner disease? Read more here! www.respiratoryfutures.org.uk/features/dia...
Reposted by Sanjay Popat
We really need to make sure people know this!! It’s never too late to quit smoking. Treating tobacco dependence is cancer treatment! We would not let this survival benefit pass us by of this was a new oncology drug. #BTOG25
So what's the point in quitting smoking once you've already been diagnosed with cancer?
Quitting in the first 6 months could add extra years to survival!
#BTOG25
Quitting in the first 6 months could add extra years to survival!
#BTOG25
March 5, 2025 at 10:03 AM
We really need to make sure people know this!! It’s never too late to quit smoking. Treating tobacco dependence is cancer treatment! We would not let this survival benefit pass us by of this was a new oncology drug. #BTOG25
Reposted by Sanjay Popat
So what's the point in quitting smoking once you've already been diagnosed with cancer?
Quitting in the first 6 months could add extra years to survival!
#BTOG25
Quitting in the first 6 months could add extra years to survival!
#BTOG25
March 5, 2025 at 9:16 AM
So what's the point in quitting smoking once you've already been diagnosed with cancer?
Quitting in the first 6 months could add extra years to survival!
#BTOG25
Quitting in the first 6 months could add extra years to survival!
#BTOG25
Reposted by Sanjay Popat
@stephenvliu.bsky.social on excitement in the Small Cell arena. PDL1/PD1 inhibition a practice changer, but so many potential game changers on the horizon from BITES To ADC, it’s exciting to see new drugs for an area of unmet need #BTOG25
March 5, 2025 at 12:09 PM
@stephenvliu.bsky.social on excitement in the Small Cell arena. PDL1/PD1 inhibition a practice changer, but so many potential game changers on the horizon from BITES To ADC, it’s exciting to see new drugs for an area of unmet need #BTOG25